David Yates Graham (David Y Graham, D Y Graham)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 73

Top Topics

Antimicrobial Resistance

Systematic Review

Helicobacter Pylori

Top Venues

Expert review of gastroenterology & hepatology

Alimentary pharmacology & therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

David Yates Graham, Yi-Chia Lee
Commentary on: the management of patients with gastric intestinal metaplasia. Gut (2024)
Massimo Rugge, Robert M Genta, Peter Malfertheiner, Mario Dinis-Ribeiro, Hashem El-Serag, David Yates Graham, Ernst J Kuipers, Wai Keung Leung, Jin Young Park, Theodore Rokkas, Christian Schulz, Emad M El-Omar, null null, null null
RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut 73 (3) (2024)
Theodore Rokkas, Konstantinos Ekmektzoglou, Yaron Niv, David Yates Graham
Comparative efficacy and safety of Potassium-Competitive Acid Blocker (P-CAB) based dual, triple and quadruple regimens for first line H. pylori infection treatment: A systematic review and network meta-analysis. The American journal of gastroenterology (2024)
Massimo Rugge, Robert M Genta, Peter Malfertheiner, Mario Dinis-Ribeiro, Hashem El-Serag, David Yates Graham, Ernst J Kuipers, Wai Keung Leung, Jin Young Park, Theodore Rokkas, Christian Schulz, Emad M El-Omar, null null, null null
RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut 73 (3) (2024)
Giovanni Mario Pes, Fasiha Kanwal, David Yates Graham
Self-Correcting Method for Highly Effective Office-Based Helicobacter pylori Therapy Using Cumulative Test of Cure Data. Helicobacter 29 (4) (2024)
Massimo Rugge, Robert M Genta, Peter Malfertheiner, Mario Dinis-Ribeiro, Hashem El-Serag, David Yates Graham, Ernst J Kuipers, Wai Keung Leung, Jin Young Park, Theodore Rokkas, Christian Schulz, Emad M El-Omar, null null, null null
RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut 73 (3) (2024)
Massimo Rugge, Robert M Genta, Peter Malfertheiner, Mario Dinis-Ribeiro, Hashem El-Serag, David Yates Graham, Ernst J Kuipers, Wai Keung Leung, Jin Young Park, Theodore Rokkas, Christian Schulz, Emad M El-Omar, null null, null null
RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut 73 (3) (2024)
Massimo Rugge, Robert M Genta, Peter Malfertheiner, Mario Dinis-Ribeiro, Hashem El-Serag, David Yates Graham, Ernst J Kuipers, Wai Keung Leung, Jin Young Park, Theodore Rokkas, Christian Schulz, Emad M El-Omar, null null, null null
RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut (2024)
Sepehr Tirgar Fakheri, Hajar Shokri-Afra, David Yates Graham, Zohreh Bari, Hafez Fakheri
A pilot study evaluating high dose esomeprazole, bismuth subcitrate and amoxicillin for eradicating Helicobacter pylori infection in Iran. Helicobacter 29 (1) (2024)
David Yates Graham, Saleh A Naser, Thomas J Borody, Zbigniew Hebzda, Harry Sarles, Scott Levenson, Robert Hardi, Tomasz Arłukowicz, Petar Svorcan, Reza Fathi, Aida Bibliowicz, Patricia Anderson, Patrick McLean, Clara Fehrmann, M Scott Harris, Shuhong Zhao, Ira N Kalfus
Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn's Disease. Antibiotics (Basel, Switzerland) 13 (8) (2024)
Sepehr Tirgar Fakheri, Hajar Shokri-Afra, David Yates Graham, Zohreh Bari, Hafez Fakheri
A pilot study evaluating high dose esomeprazole, bismuth subcitrate and amoxicillin for eradicating Helicobacter pylori infection in Iran. Helicobacter 29 (1) (2024)
Massimo Rugge, Robert M Genta, Peter Malfertheiner, Mario Dinis-Ribeiro, Hashem El-Serag, David Yates Graham, Ernst J Kuipers, Wai Keung Leung, Jin Young Park, Theodore Rokkas, Christian Schulz, Emad M El-Omar, null null, null null
RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut 73 (3) (2024)
Massimo Rugge, Robert M Genta, Peter Malfertheiner, Mario Dinis-Ribeiro, Hashem El-Serag, David Yates Graham, Ernst J Kuipers, Wai Keung Leung, Jin Young Park, Theodore Rokkas, Christian Schulz, Emad M El-Omar, null null, null null
RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut 73 (3) (2024)
David Yates Graham, Saleh A Naser, Thomas J Borody, Zbigniew Hebzda, Harry Sarles, Scott Levenson, Robert Hardi, Tomasz Arłukowicz, Petar Svorcan, Reza Fathi, Aida Bibliowicz, Patricia Anderson, Patrick McLean, Clara Fehrmann, M Scott Harris, Shuhong Zhao, Ira N Kalfus
Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn's Disease. Antibiotics (Basel, Switzerland) 13 (8) (2024)
Massimo Rugge, Robert M Genta, Peter Malfertheiner, Mario Dinis-Ribeiro, Hashem El-Serag, David Yates Graham, Ernst J Kuipers, Wai Keung Leung, Jin Young Park, Theodore Rokkas, Christian Schulz, Emad M El-Omar, null null, null null
RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut 73 (3) (2024)
David Yates Graham
After 28 Years, Professor David Y. Graham Says Goodbye and Helicobacter Welcomes a New Editor. Helicobacter 29 (3) (2024)
Massimo Rugge, Robert M Genta, Peter Malfertheiner, Mario Dinis-Ribeiro, Hashem El-Serag, David Yates Graham, Ernst J Kuipers, Wai Keung Leung, Jin Young Park, Theodore Rokkas, Christian Schulz, Emad M El-Omar, null null, null null
RE.GA.IN.: the Real-world Gastritis Initiative-updating the updates. Gut 73 (3) (2024)
Theodore Rokkas, David Yates Graham
How widespread and convenient H. pylori susceptibility testing will result in pharmacological opportunities. Expert review of gastroenterology & hepatology 17 (1) (2023)
David Yates Graham, Theodore Rokkas
Response to: a true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication. Expert review of gastroenterology & hepatology 17 (3) (2023)
Wei-Yi Lei, Jian-Yu Lee, Shu-Ling Chuang, Ming-Jong Bair, Chien-Lin Chen, Jeng-Yih Wu, Deng-Chyang Wu, Felice Tien O'Donnell, Hui-Wen Tien, Yi-Ru Chen, Tsung-Hsien Chiang, Yu-Hsin Hsu, Tsui-Hsia Hsu, Pei-Chun Hsieh, Li-Ju Lin, Shu-Li Chia, Chao-Chun Wu, Yi-Maun Subeq, Shu-Hui Wen, Hsiu-Chun Chang, Yu-Wen Lin, Kuo-Ping Sun, Chia-Hsiang Chu, Ming-Shiang Wu, David Yates Graham, Tony Hsiu-Hsi Chen, Yi-Chia Lee
Eradicating Helicobacter pylori via 13 C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case method. Gut (2023)
David Yates Graham
Implications of the paradigm shift in management of Helicobacter pylori infections. Therapeutic advances in gastroenterology 16 (2023)
Theodore Rokkas, David Yates Graham
How widespread and convenient H. pylori susceptibility testing will result in pharmacological opportunities. Expert review of gastroenterology & hepatology 17 (1) (2023)
Theodore Rokkas, David Yates Graham
How widespread and convenient H. pylori susceptibility testing will result in pharmacological opportunities. Expert review of gastroenterology & hepatology 17 (1) (2023)
Theodore Rokkas, David Yates Graham
How widespread and convenient H. pylori susceptibility testing will result in pharmacological opportunities. Expert review of gastroenterology & hepatology (2023)
David Yates Graham
Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates. Digestive diseases and sciences (2023)
Theodore Rokkas, David Yates Graham
How widespread and convenient H. pylori susceptibility testing will result in pharmacological opportunities. Expert review of gastroenterology & hepatology 17 (1) (2023)
Massimo Rugge, Robert M Genta, Peter Malfertheiner, David Yates Graham
Atrophic autoimmune gastritis: 'a muddled or misguided core concept compromises our overall comprehension of the problem'. Gut (2023)
David Yates Graham, Theodore Rokkas
Response to: A true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication. Expert review of gastroenterology & hepatology (2023)
David Yates Graham
Implications of the paradigm shift in management of Helicobacter pylori infections. Therapeutic advances in gastroenterology 16 (2023)
David Yates Graham, Theodore Rokkas
Response to: a true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication. Expert review of gastroenterology & hepatology (2023)
David Yates Graham, Theodore Rokkas
Response to: a true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication. Expert review of gastroenterology & hepatology 17 (3) (2023)
Theodore Rokkas, David Yates Graham
How widespread and convenient H. pylori susceptibility testing will result in pharmacological opportunities. Expert review of gastroenterology & hepatology 17 (1) (2023)
David Yates Graham
Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates. Digestive diseases and sciences (2023)
Sarita Ratana-Amornpin, Likasith Sanglutong, Thanee Eiamsitrakoon, Sith Siramolpiwat, David Yates Graham, Varocha Mahachai
Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. Helicobacter (2023)
David Yates Graham
It Is Time for a Paradigm Shift in Design, Execution, and Publishing of Comparative Helicobacter pylori Treatment Trials. The American journal of gastroenterology (2023)
Massimo Rugge, Robert M Genta, Peter Malfertheiner, David Yates Graham
Gastric cancer risk in autoimmune gastritis: evidence versus opinion. Gut (2023)
David Yates Graham, Theodore Rokkas
Response to: a true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication. Expert review of gastroenterology & hepatology 17 (3) (2023)
David Yates Graham, Steven F Moss
Antimicrobial Susceptibility Testing for Helicobacter pylori Is Now Widely Available: When, How, Why. The American journal of gastroenterology 117 (4) (2022)
Theodore Rokkas, Konstantine Ekmektzoglou, David Yates Graham
Current role of tailored therapy in treating Helicobacter pylori infections. A systematic review, meta-analysis and critical analysis. Helicobacter (2022)
David Yates Graham
Quality of Studies for Gastric pH Measurements With Vonoprazan. The American journal of gastroenterology 117 (11) (2022)
Massimo Rugge, Robert M Genta, Peter Malfertheiner, David Yates Graham
Steps forward in understanding gastric cancer risk. Gut (2022)
Massimo Rugge, Ludovica Bricca, Stefano Guzzinati, Diana Sacchi, Marco Pizzi, Edoardo Savarino, Fabio Farinati, Manuel Zorzi, Matteo Fassan, Angelo Paolo Dei Tos, Peter Malfertheiner, Robert M Genta, David Yates Graham
Autoimmune gastritis: long-term natural history in naïve Helicobacter pylori -negative patients. Gut (2022)
Giovanni Mario Pes, David Yates Graham
Modern approach to the diagnosis of Helicobacter pylori infection. Alimentary pharmacology & therapeutics (2022)
David Yates Graham, Fasiha Kanwal, Theodore Rokkas
Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy. Gut (2021)
David Yates Graham
Helicobacter pylori. Current topics in microbiology and immunology (2021)
David Yates Graham
Comments regarding use of rifabutin for Helicobacter pylori eradication. Therapeutic advances in gastroenterology 14 (2021)
Ritwick Agrawal, Nadim J Ajami, Sonal Malhotra, Liang Chen, Donna L White, Amir Sharafkhaneh, Kristi L Hoffman, David Yates Graham, Hashem B El-Serag, Joseph F Petrosino, Li Jiao
Habitual Sleep Duration and the Colonic Mucosa-Associated Gut Microbiota in Humans-A Pilot Study. Clocks & sleep 3 (3) (2021)
Akiko Shiotani, Priya Roy, Hong Lu, David Yates Graham
Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship. Therapeutic advances in gastroenterology 14 (2021)
Tsung-Hsien Chiang, Chieh-Chang Chen, Ping-Huei Tseng, Jyh-Ming Liou, Ming-Shiang Wu, Chia-Tung Shun, Yi-Chia Lee, David Yates Graham
Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study. Helicobacter 26 (3) (2021)
Hong Lu, David Yates Graham
Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment-authors' reply. Alimentary pharmacology & therapeutics 50 (3) (2020)
Jyh-Ming Liou, Peter Malfertheiner, Yi-Chia Lee, Bor-Shyang Sheu, Kentaro Sugano, Hsiu-Chi Cheng, Khay-Guan Yeoh, Ping-I Hsu, Khean-Lee Goh, Varocha Mahachai, Takuji Gotoda, Wei-Lun Chang, Mei-Jyh Chen, Tsung-Hsien Chiang, Chieh-Chang Chen, Chun-Ying Wu, Alex Hwong-Ruey Leow, Jeng-Yih Wu, Deng-Chyang Wu, Tzu-Chan Hong, Hong Lu, Ari Fahrial Syam, Francis Megraud, Francis Ka Leung Chan, Joseph Jy Sung, Jaw-Town Lin, David Yates Graham, Ming-Shiang Wu, Emad M El-Omar, null null
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut 69 (12) (2020)
David Yates Graham, Francis Mégraud
Classification system for Helicobacter pylori therapies: Compared and contrasted to traditional infectious disease therapy. Helicobacter 26 (1) (2020)
David Yates Graham, Hong Lu, Akiko Shiotani
Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. Journal of gastroenterology and hepatology 36 (5) (2020)
Tsung-Hsien Chiang, Wei-Jung Chang, Sam Li-Sheng Chen, Amy Ming-Fang Yen, Jean Ching-Yuan Fann, Sherry Yueh-Hsia Chiu, Yi-Ru Chen, Shu-Ling Chuang, Chun-Fu Shieh, Cheng-Ying Liu, Han-Mo Chiu, Hung Chiang, Chia-Tung Shun, Ming-Wei Lin, Ming-Shiang Wu, Jaw-Town Lin, Chang-Chuan Chan, David Yates Graham, Tony Hsiu-Hsi Chen, Yi-Chia Lee
Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut 70 (2) (2020)
Cai-Ping Gao, Di Zhang, Ting Zhang, Jin-Xia Wang, Sheng-Xi Han, David Yates Graham, Hong Lu
PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter 25 (4) (2020)
David Yates Graham, Hashem B El-Serag
European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners. Gut 70 (1) (2020)
Neville D Yeomans, David Yates Graham
Editorial: gastrointestinal safety of COX-2 selective and nonselective NSAIDs-the impact of the PRECISION trial. Authors' reply. Alimentary pharmacology & therapeutics 47 (11) (2019)
Takahiro Uotani, Kosuke Murakami, Tomohisa Uchida, Shingo Tanaka, Hiroyuki Nagashima, Xi-Lei Zeng, Junko Akada, Mary K Estes, David Yates Graham, Ari Fahrial Syam
Changes of tight junction and interleukin-8 expression using a human gastroid monolayer model of Helicobacter pylori infection. Helicobacter 24 (3) (2019)
Lou Yu, Laisheng Luo, Xiaohua Long, Xiao Liang, Yingjie Ji, David Yates Graham, Hong Lu
High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial. Helicobacter 24 (4) (2019)
Giovanni Mario Pes, Stefano Bibbo, Giovanni Mario Pes, Ruggero Francavilla, David Yates Graham
Role of Probiotics in Helicobacter pylori Eradication: Lessons from a Study of Lactobacillus reuteri Strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a Proton-Pump Inhibitor. The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale 2019 (2019)
Qi Chen, Xiaohua Long, Yingjie Ji, Xiao Liang, Dongping Li, Hong Gao, Beili Xu, Ming Liu, Ying Chen, Yunwei Sun, Yan Zhao, Gang Xu, Yanyan Song, Lou Yu, Wei Zhang, Wenzhong Liu, David Yates Graham, Hong Lu
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Alimentary pharmacology & therapeutics 49 (11) (2019)
Massimo Rugge, Diana Sacchi, David Yates Graham, Robert M Genta
Secondary prevention of gastric cancer: merging the endoscopic atrophic border with OLGA staging. Gut 69 (6) (2019)
Giovanni Mario Pes, Stefano Bibbò, Mariafrancesca Loria, Roberta Salis, Alessandra Manca, Giovanni Mario Pes, David Yates Graham
Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies. Helicobacter 24 (6) (2019)
Mimi Chang Tan, David Yates Graham
Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer. BMJ evidence-based medicine 23 (3) (2018)
Antone R Opekun, Savannah A Gonzales, Mahmoud A Al-Saadi, David Yates Graham
Brief report: Lactobacillus bulgaricus GLB44 (Proviotic™ ) plus esomeprazole for Helicobacter pylori eradication: A pilot study. Helicobacter 23 (2) (2018)
Neville D Yeomans, David Yates Graham, M E Husni, D H Solomon, T Stevens, J Vargo, Q Wang, L M Wisniewski, K E Wolski, J S Borer, P Libby, A M Lincoff, T F Lüscher, W Bao, C Walker, S E Nissen, null null
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Alimentary pharmacology & therapeutics 47 (11) (2018)
David Yates Graham, Hong Lu, Giovanni Mario Pes
Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter 24 (1) (2018)
Kamran Ayub, Gyanprakash Ketwaroo, Suhaib Abudayyeh, Abeer Ibrahim, Rhonda A Cole, Rosetta Brumfield-Brown, Waqar A Qureshi, Linda Rabeneck, David Yates Graham
Mechanical colon cleansing for screening colonoscopy: A randomized controlled trial. Journal of digestive diseases 18 (12) (2018)
Yi-Chia Lee, Masahiro Asaka, David Yates Graham
Editorial: Helicobacter pylori and gastric cancer in Alaskan Natives: Time to stop studying H. pylori and to eradicate it. Helicobacter 23 (3) (2018)
David Yates Graham, Gyanprakash A Ketwaroo, Mary E Money, Antone R Opekun
Enzyme therapy for functional bowel disease-like post-prandial distress. Journal of digestive diseases 19 (11) (2018)
Alex H-R Leow, Ahmad N Azmi, Mun-Fai Loke, Jamuna Vadivelu, David Yates Graham, Khean-Lee Goh
Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? Journal of digestive diseases 19 (11) (2018)
David Yates Graham
Letter: questions regarding the diagnostic performance of serum assays for atrophic gastritis. Alimentary pharmacology & therapeutics 46 (11-12) (2017)
Y Hu, J-H Wan, X-Y Li, Y Zhu, David Yates Graham, Nong Hua Lu
Editorial: recurrence of Helicobacter pylori infection-still the same after all these years… Authors' reply. Alimentary pharmacology & therapeutics 47 (1) (2017)